New drug BL-M17D1 tested in patients with Hard-to-Treat cancers

NCT ID NCT06503783

Recruiting now Disease control Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase I trial is testing a new drug called BL-M17D1 in 20 people with advanced breast cancer (HER2-positive or negative) or other solid tumors that have spread. The main goals are to check the drug's safety, find the right dose, and see early signs of whether it shrinks tumors. Participants receive the drug by IV every 3 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: BL-M17D1 (a drug given by IV infusion every 3 weeks)
What this could lead to: If it works, this could point toward a new treatment option for advanced breast cancer and other solid tumors that have not responded to standard therapies.
What could go wrong: This is a very early Phase I trial with only 20 participants, so it is primarily testing safety and dosing. The drug may not prove effective, and side effects could be significant.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm HER2 positive breast carcinoma Her2-receptor negative breast cancer neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER SOLID TUMOR

Contacts and locations

Locations

Fudan University Shanghai Cancer Center
RECRUITING

Shanghai, Shanghai Municipality, China
Harbin Medical University Cancer Hospital
RECRUITING

Harbin, Heilongjiang, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.